Chagas' disease is responsible for significant mortality and morbidity in Latin America.
Current treatments display variable efficacy and have adverse side effects, hence more …

Novel technologies that include recombinant pathogens and rapid detection methods are
contributing to the development of drugs for neglected diseases. Recently, the results from …

The discovery of new therapeutic options against Trypanosoma cruzi, the causative agent of
Chagas disease, stands as a fundamental need. Currently, there are only two drugs …

Chagas disease is a significant health problem in Latin America and the available
treatments have significant issues in terms of toxicity and efficacy. There is thus an urgent …

Advocacy for better drugs and access to treatment has boosted the interest in drug discovery
and development for Chagas disease, a chronic infection caused by the genetically …

The development of new drugs against Chagas disease is a priority since the currently
available medicines have toxic effects, partial efficacy and are targeted against the acute …

Human American trypanosomiasis, commonly called Chagas disease, is one of the most
neglected illnesses in the world and remains one of the most prevalent chronic infectious …

Introduction: Chagas disease is the highest impact human infectious disease in Latin
America, and the leading worldwide cause of myocarditis. Despite the availability of several …

Cell-based screening has become the major compound interrogation strategy in Chagas
disease drug discovery. Several different cell lines have been deployed as host cells in …

Recent clinical trials investigating treatment of chronic indeterminate Chagas disease with
two re-purposed azole anti-fungal drugs, posaconazole and ravuconazole, revealed their …